ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Clazakizumab (CLZ, Anti-IL-6 Monoclonal Antibody) Treatment of Patients (Pts) with Chronic Antibody-Mediated Rejection (cABMR) Reduces Total Immunoglobulin (Ig) and Anti-HLA IgG Antibody Levels

B. Shin, N. F. Ammerman, A. A. Vo, X. Zhang, S. C. Jordan, M. Toyoda

Cedars-Sinai Medical Center, Los Angeles, CA

Meeting: 2019 American Transplant Congress

Abstract number: A193

Keywords: Antibodies, IgG, Immunoglobulins (Ig), Kidney

Session Information

Date: Saturday, June 1, 2019

Session Name: Poster Session A: Kidney Chronic Antibody Mediated Rejection

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall C & D

Related Abstracts
  • Monitoring Inflammatory Cytokine Levels in Kidney Transplant Patients (KTx Pts) with Chronic Antibody Mediated Rejection (cABMR) Treated with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody)
  • Tocilizmab (Anti-IL-6R) Treatment (TCZ-Rx) Reduced Total IgG Levels Including Anti-HLA IgG: Analysis of IgG Subclasses (IgG1-IgG4) and Anti-HLA IgG Subclasses Show Similar Reductions in All Subclasses from Patients with DSA+ Chronic Antibody-Mediated Rejection (CABMR).

*Purpose: We have recently reported successful use of Tocilizumab (TCZ), an anti-IL-6 receptor (R) monoclonal antibody, for cABMR treatment in HLA-sensitized kidney transplant (KTx) Pts. Total IgG, anti-HLA IgG and IgG subclasses were significantly reduced post-TCZ. CLZ is 3-120 times more potent than TCZ in inhibiting IL-6/IL-6R signaling in vitro. A clinical trial aimed at improving cABMR using CLZ in sensitized KTx Pts is now underway. Here, we report on measurement of IgG, IgM, IgA, IgG subclasses, anti-HLA IgG and donor specific antibody (DSA) levels pre- and post-CLZ treatment of Pts with cABMR.

*Methods: Plasma samples obtained pre- & at 6 months post-CLZ (25mg SQ, monthly) from 7 Pts with cABMR were tested for total IgG, IgM, IgA and IgG1-4 subclasses by ELISA. Anti-HLA IgG and DSAs were measured by single bead Luminex assay. The anti-HLA IgG and DSA (class I & class II) levels were expressed as a relative intensity score; Score 10, 5, 2 and 0 for MFI >10K, 5K-10K, <5K and no HLA antibody, respectively, are given to each detected antibody, and the sum of these are the final score for plasma with multiple HLA antibodies.

*Results: Total IgG, IgG1 and IgG2 significantly decreased post-CLZ, while no reduction was seen in total IgM, IgA, IgG3 and IgG4 (Table 1). Anti-HLA IgG was also significantly reduced post-CLZ; 4 of 7 Pts (57%) showed reduction post-CLZ and the remaining 3 pts with low scores (<6) no change. DSA was reduced post-CLZ in 2 Pts, and 3 with DSA and 2 without DSA showed no change.

*Conclusions: CLZ suppresses Ig production including total IgG, IgG1, IgG2, anti-HLA IgG and DSA likely due to non-specific B cell suppression by blocking the effect of IL-6. This may contribute to improvement of cABMR in this Pt population. A larger study with longer follow-up is required for confirming the findings.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Shin B, Ammerman NF, Vo AA, Zhang X, Jordan SC, Toyoda M. Clazakizumab (CLZ, Anti-IL-6 Monoclonal Antibody) Treatment of Patients (Pts) with Chronic Antibody-Mediated Rejection (cABMR) Reduces Total Immunoglobulin (Ig) and Anti-HLA IgG Antibody Levels [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/clazakizumab-clz-anti-il-6-monoclonal-antibody-treatment-of-patients-pts-with-chronic-antibody-mediated-rejection-cabmr-reduces-total-immunoglobulin-ig-and-anti-hla-igg-antibody-levels/. Accessed February 28, 2021.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.